Literature DB >> 7813075

Structural and functional polymorphism of lipoprotein(a): biological and clinical implications.

A M Scanu1.   

Abstract

Lipoprotein(a) [Lp(a)], a variant of low-density lipoprotein, is heterogeneous in density because of variability in the content and composition of its core lipids and size polymorphism of its specific glycoprotein component, apolipoprotein(a) [apo(a)]. In some individuals, density polymorphism may also derive from the fact that Lp(a) contains 2 mol of apo(a) per mole of apoB100, contrary to the more common 1:1 molar stoichiometry. Moreover, the size of apo(a) is polymorphic because of variations in the number of kringle 4 type 2 repeats. Another type of apo(a) polymorphism is related to sequence mutations at the kringle level. Two mutations can occur in kringle 4 type 10: one, Trp72-->Arg, is affiliated with an Lp(a) that is lysine-binding defective; the other, Met66-->Thr, with a normal lysine-binding function. Thus, Lp(a) is structurally and functionally polymorphic, a notion that must be considered in assessing the cardiovascular pathogenicity of this lipoprotein variant and in immunoquantification assays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7813075

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  An application of apo(a) isoforms for the clinical assessment of Lp(a).

Authors:  S Takayama; Y Yasumuro; J h Kim; M Ishikawa; D Tsujino; S Matsuo; Y Harada; S Sugii
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients.

Authors:  Jim Joseph; Farzana Ganjifrockwala; Grace George
Journal:  Oxid Med Cell Longev       Date:  2016-10-19       Impact factor: 6.543

3.  Lipoprotein(a) and lipid profiles of patients awaiting coronary artery bypass graft; a cross sectional study.

Authors:  E M S Bandara; S Ekanayake; C A Wanigatunge; A Kapuruge
Journal:  BMC Cardiovasc Disord       Date:  2016-11-08       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.